![](http://www.biohealthcapital.com/wp-content/uploads/2018/07/qiagen-logo.png)
QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today introduced seamless next-generation sequencing (NGS) solutions for a wide range of hereditary diseases on the GeneReader NGS System, the complete Sample to Insight NGS solution for any lab worldwide.